Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Democratic Female Senators Praise Supreme Court Nominee Sotomayor
Several Democratic female senators on Wednesday took to the floor in a series of speeches praising Supreme Court nominee Sonia Sotomayor and highlighting her judicial qualifications, the Boston Globe"s "Political Intelligence" reports. Sen. Amy Klobuchar (Minn.) -- a member of the Senate Judiciary Committee -- was joined by Sens. Mary Landrieu (La.), Claire McCaskill (Mo.) and Jeanne Shaheen (N.H.).In her address, Klobuchar said that Sotomayor"s experience "particularly resonated with me," adding that Sotomayor "understands the law is not just some dusty book in your basement" and that its interpretation has consequences. McCaskill said that Sotomayor is a nominee with "integrity, grit, intellect and the ability to pass judgment in the most difficult intellectual challenges that face a Supreme Court justice."According to "Political Intelligence," the floor speeches came after Klobuchar and others praised Sotomayor"s nomination at Monday"s annual convention of the left-leaning legal organization the American Constitution Society. In her speech, Klobuchar defended Sotomayor against conservative critics who have questioned the nominee"s temperament, citing complaints that Sotomayor was impatient with unprepared lawyers. Klobuchar said that she is "hoping that we would get to a point in this country where we could be appointing and confirming as many as rough and to-the-point female judges as we have appointed male judges" ("Political Intelligence," Boston Globe, 6/24).

Cancer Vaccines Led To Long-Term Survival For Patients With Metastatic Melanoma, Study Shows
Hoag Memorial Hospital Presbyterian announced promising data from a clinical study showing patient-specific cancer vaccines derived from patients" own cancer cells and immune cells were well tolerated and resulted in impressive long-term survival rates in patients with metastatic melanoma whose disease had been minimized by other therapies.
News of the day
Government Of Canada Approves A New Of Medical Isotopes
The Honourable Leona Aglukkaq, Minister of Health, announced the approval of a new of Technetium-99m (Tc-99m) for Canada.
Health Insurance

Echo Therapeutics To Present At Prestigious 'Innovations In Diabetes' Conference

Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system, announced that Patrick T. Mooney, M.D., Chairman and Chief Executive Officer, will present at the "Innovations in Diabetes" Conference on, Tuesday, July 14, 2009 at 5:30 pm ET. The presentation will occur live and will be held at The Pier V Hotel at the Inner Harbor in Baltimore. "We are honored to have been selected to present at this prestigious conference which highlights cutting edge technologies in the field of diabetes management," stated Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics. "We look forward to introducing Symphony, our needle-free, continuous glucose monitoring technology, to the large audience of physician thought-leaders from around the world who will be attending the conference, and to providing an update on our notable progress toward our goal of making Symphony available to physicians and patients in early 2010." About Echo Therapeutics Echo Therapeutics is focused on medical devices and specialty pharmaceuticals. Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude(TM) SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products. About Innovara Innovara, Inc. is a global strategic consulting, educational development, and business development corporation specializing in forming unique alliances between MDs and medical institutions involved in medical research and education, with the aim of aiding advancing medical education, disease management and patient care worldwide. Innovara was founded over 25 years ago and is dedicated to working with globally recognized medical institutions, physicians, health care and other professionals, bringing the "latest from the best" in medical education and advances in research to physicians and other healthcare professionals around the world. Cautionary Statement Regarding Forward Looking Statements The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo"s ongoing studies, including the efficacy of Echo"s Symphony tCGM System, the failure of future development and preliminary marketing efforts related to Echo"s Symphony tCGM System, the ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo"s ability to develop, market and sell diagnostic products based on its skin permeation platform technologies, including the Symphony tCGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM System. These and other risks and uncertainties are identified and described in more detail in Echo"s filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2008, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements. Echo Therapeutics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009